Inner City Asthma Consortium

内城哮喘协会

• 批准号: 8938738
• 负责人: William W. Busse
• 金额: $ 200万
• 依托单位: UNIVERSITY OF WISCONSIN-MADISON
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-30 至 2014-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8938738
• 关键词: 1 year old; 2 year old; 3 year old; 4 year old; Adolescence; Age; Asthma; Biological Markers; Child; Childhood; Clinical Research; Clinical Trials; Conduct Clinical Trials; Disease; Immune; Measures; Minority; Onset of illness; Population; Research; Safety; Severities; Staging; Therapeutic Effect; United States; base; inner city; prevent

The objectives of the Inner City Asthma Consortium are to implement a long range scientific plan to reduce asthma severity and prevent asthma among inner city children and to identify the mechanisms involved in the immunopathogenesis of asthma in these populations. The specific objectives are to: 1) conduct clinical trials to evaluate the safety and efficacy of promising immune based therapies in reducing asthma severity and preventing disease onset in minority children residing in inner cities in the United States; 2) conduct research to delineate the underlying mechanisms of such therapies as an integral part of the clinical trials undertaken by the Consortium; 3) conduct clinical studies on the immunopathogenesis of asthma onset, progression and severity ; and 4) develop and validate surrogate / biomarkers to measure disease stage, progression and therapeutic effect.

内城哮喘联盟的目标是实施一项远程科学计划，以降低哮喘的严重程度和预防内城儿童之间的哮喘，并确定这些人群中哮喘的免疫发病发生的机制。具体目标是：1）进行临床试验，以评估有前途的基于免疫疗法在减轻哮喘严重程度和预防美国内城少数族裔儿童的疾病发作方面的安全性和功效； 2）进行研究，以将这种疗法的基本机制描述为财团进行的临床试验不可或缺的一部分； 3）对哮喘发作，进展和严重程度的免疫发病发生进行临床研究； 4）开发和验证替代 /生物标志物以测量疾病阶段，进展和治疗作用。